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Abstract
Background: Our objective was to develop an instrument to assess the methodological quality of
systematic reviews, building upon previous tools, empirical evidence and expert consensus.
Methods: A 37-item assessment tool was formed by combining 1) the enhanced Overview Quality
Assessment Questionnaire (OQAQ), 2) a checklist created by Sacks, and 3) three additional items
recently judged to be of methodological importance. This tool was applied to 99 paper-based and
52 electronic systematic reviews. Exploratory factor analysis was used to identify underlying
components. The results were considered by methodological experts using a nominal group
technique aimed at item reduction and design of an assessment tool with face and content validity.
Results: The factor analysis identified 11 components. From each component, one item was
selected by the nominal group. The resulting instrument was judged to have face and content
validity.
Conclusion: A measurement tool for the 'assessment of multiple systematic reviews' (AMSTAR)
was developed. The tool consists of 11 items and has good face and content validity for measuring
the methodological quality of systematic reviews. Additional studies are needed with a focus on the
reproducibility and construct validity of AMSTAR, before strong recommendations can be made
on its use.
Background
It has been estimated that healthcare professionals
attempting to keep abreast of their field would need to
read an average of 17–20 original articles every day [1].
Increasingly, systematic reviews are being advocated as a
way to keep up with current medical literature [2]. A well
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lated question by analyzing all available evidence. It
employs an objective search of the literature,  applying
predetermined inclusion and exclusion criteria to the lit-
erature, critically appraising what is found to be relevant.
It then extracts and synthesizes data from the available
evidence base to formulate findings [3].
However, in spite of the care with which they are con-
ducted, systematic reviews may differ in quality, and yield
different answers to the same question [4]. As a result,
users of systematic reviews should be critical and look
carefully at the methodological quality of the available
reviews [5].
A decade has passed since the initial development of tools
to assess the quality of systematic reviews, such as those
created by Oxman and Guyatt [6] and Sacks [7]. There are
now more than 24 instruments available to assess the
quality of systematic reviews [8]. Nevertheless, the major-
ity of the available instruments are not widely used. Sev-
eral are lengthy and include complicated instructions for
their use. Furthermore, since their development, consider-
able empirical research has accumulated about potential
sources of bias in systematic reviews. For example, recent
methodological research has highlighted the potential
importance of publication language and publication bias
in systematic reviews [9-11].
Therefore, our goal was to develop a new instrument for
assessing the methodological quality of systematic
reviews by building upon empirical data collected with
previously developed tools and utilizing expert opinion.
This goal was pursued by two study objectives. Our first
objective was to assess a large sample of systematic
reviews using an item pool drawn from two available
instruments used to assess methodological quality, sup-
plemented by additional items judged to be needed on
the basis of recent publications. We used exploratory fac-
tor analysis to identify the underlying component struc-
ture. Our second objective was to build on the results of
this factor analysis, by using experts in a nominal group
technique (NGT) to reduce the items pool and to decide
on a new assessment tool with face and content validity.
Methods
We designed a 37-item assessment tool that we developed
by combining items from two available instruments: the
enhanced Overview Quality Assessment Questionnaire
(OQAQ) [8] containing 10 items and a checklist created
by Sacks [7] containing 24 items. We supplemented this
with three additional items based upon methodological
advances in the field since the development of the original
two instruments: Language restriction: Language restriction
in systematic reviews remains controversial. Some studies
have suggested that systematic reviews that include only
English language publications tend to overestimate effect
sizes [10], whereas other studies suggest that such lan-
guage restrictions may not do so [11]. An item was added
to determine whether a language restriction was applied
in selecting studies for the systematic review. 2) Publica-
tion bias: Publication bias refers to the tendency for
research with negative findings to get published less fre-
quently, less prominently, or more slowly, and the ten-
dency for research with positive findings to get published
more than once. Publication bias has been identified as a
major threat to the validity of systematic reviews. Empiri-
cal research suggests that publication bias is widespread,
and that a variety of methods are now available to assess
publication bias [12-19]. An item was added to determine
whether the authors assessed the likelihood of publica-
tion bias. 3) Publication status of studies suggests that pub-
lished trials are generally larger and may show an overall
greater treatment effect than studies published in the 'grey'
literature [20]. The importance of including grey literature
in all systematic reviews has been discussed [21]. The
assessment of the inclusion of grey literature considers
whether or not the authors reported searching for grey lit-
erature.
Objective 1
The 37-item assessment tool was used to appraise 99
paper-based reviews identified from a database of reviews
and meta-analyses [22] and 52 Cochrane systematic
reviews from the Cochrane Database of Systematic
Reviews [9]. After the list of selected systematic reviews
was generated, full copies of these were retrieved, copied,
and masked to conceal author, institution, and journal.
Reviews in languages other than English (i.e., French, Ger-
man, and Portuguese) were translated into English with
the assistance of colleagues before masking [23].
For each included systematic review, two reviewers inde-
pendently assessed the methodological quality with the
37 items (CH, BS).
Statistical analyses and graphs displaying the results
obtained were produced using SPSS version 13.0 for Win-
dows. The 37 items were subjected to principal compo-
nents analysis, and Varimax rotations were used to rotate
the components. Items with low factor loadings of < 0.50
were removed.
Objective 2
We convened an international panel of eleven experts in
the fields of methodological quality assessment and sys-
tematic reviews. The group was selected from three organ-
izations involved both in the conduct of systematic
reviews and in the assessment of methodological quality.Page 2 of 7
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epidemiologists, and reviewers who were new to the field.
Some individuals were previously involved in the
Cochrane Collaboration, while a number were not. By
examining the results of the factor analysis, they reflected
critically on the components identified and decided on
the items to be included in the new instrument. The nom-
inal group process took place in San Francisco during a
one day session.
We conducted the following NGT in order to achieve
agreement. After delivery of an overview of the project and
the planned process for the day, the panel reviewed the
results of the factor analysis. The aim of the NGT was to
structure interaction within the group. Firstly, each partic-
ipant was asked to record his or her ideas independently
and privately. The ideas were then listed  in a round-robin
format. One idea was collected from each individual in
turn and listed in front of the group by the facilitator, and
the process was continued until all ideas had been listed.
Individuals then privately  recorded their judgements.
Subsequent discussions took place. The individual judge-
ments were aggregated statistically to derive the group
judgements. The nominal group was also asked to agree
on a final label for each of the 11 components. A descrip-
tion was formulated for each of the items and a next-to-
final instrument was assembled. This was circulated elec-
tronically to the group for a final round of fine tuning.
Results
Objective 1
The items were subjected to factor analysis, and only those
items that loaded highly on one component (>.50) were
retained. The described factor analysis made it possible to
reduce the 37-item instrument to a shorter (29-item)
instrument that measured 11 components (Table 1).
Objective 2
The nominal group discussed all 11 components (Table
1). The items most appropriate for the components (Table
2), were included in the draft instrument [also see Addi-
tional file 1]. The instrument is an 11-item questionnaire
that asks reviewers to answer yes, no, can't answer or not
applicable. A separate question on language was identi-
fied in the factor analysis as a significant issue, but the
nominal group felt that the contradictory evidence in the
literature warranted removing this item from the short-
ened item list and capturing it under the question on pub-
lication status.
Discussion
Strengths and Weaknesses
Our purpose was to help users of systematic reviews to
critically appraise systematic reviews. Therefore, we set out
with the goal of developing a new instrument for assessing
the methodological quality of systematic reviews, by
building upon empirical data on previously developed
tools, empirical evidence and utilizing expert opinion.
Because we had already created a dataset of 151 systematic
reviews assessed using 37 completed items for each
review, we were able to conduct a factor analysis as the
first step in the creation of the new tool. A more com-
monly used approach would have been to harvest appro-
priate items from existing questionnaires. This method
has been used extensively in the development of instru-
ments for assessing the quality of both randomized and
non-randomized studies of health care interventions [24-
26]. The disadvantage of harvesting appropriate items
from existing questionnaires is that it relies heavily on the
validation of the source questionnaires [27]. Conducting
a factor analysis made it possible to determine whether
the measured dimensions could in principle be assessed
using a smaller number of items.
Traditionally, factor analysis is divided into two types of
analyses: exploratory and confirmatory. As its name indi-
cates, exploratory factor analysis aims to discover the
main constructs or dimensions of a concept by conduct-
ing a preliminary investigation of the correlations
between all the identified variables. This process is also
known as Principal Components Analysis (PCA). PCA has
been recommended for use in test construction by Kline,
as a means of condensing the correlation matrix, rather
than as an aid to the interpretation of the factor-structure
of a questionnaire [28]. Items with low factor loadings
tend to be weakly correlated with other items, and there-
fore were removed. Various rotational strategies have also
been proposed. The goal of all of them is to obtain a clear
pattern of loadings, that is, factors that are somehow
clearly marked by high loadings for some variables and
low loadings for others [29,30]. We used this approach
because it is useful when a body of theory or principles
has been established, but has not yet been operationalised
into an evaluative framework [31].
The structured-discussion format employed in this project
enabled all participants to contribute to the refining of the
assessment tool. The nominal technique followed
involved experts, discussion, and a consensus that was
qualitative in nature. Consequently, it complemented the
quantitative nature of factor analysis, and as a result the
final tool had face and content validity as judged by the
nominal consensus panel.
We recognize the need for further testing of AMSTAR.
Additional studies are necessary with a focus on the repro-
ducibility and construct validity of AMSTAR before strong
recommendations can be made on its use. The Canadian
Agency for Drugs and Technologies in Health (CADTH)Page 3 of 7
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Table 1: Items identified through the factor analysis
Original instrument (item no) 1 2 3 4 5 6 7 8 9 10 11
1 Protocol Sacks .58
2 Literature Search Sacks .82
3 List of Trials Analyzed Sacks .75
4 Log of Rejected Trials Sacks .68
5 Treatment Assignment Sacks .80
6 Ranges of Patients Sacks
7 Range of Treatment Sacks .88
8 Range of Diagnosis Sacks .80
9 CombinabilityCriteria Sacks .88
10 Measurement Sacks .57
11 Selection Bias Sacks .85
12 Data abstraction Sacks .50
13 Inter-observer Agreement Sacks .65
14 Sources of Support Sacks .64
15 Statistical Methods Sacks .81
16. Statistical Errors Sacks
17 Confidence Intervals Sacks .73
18 Subgroup Analysis Sacks
19 Quality Assessment Sacks .77
20 Varying Methods Sacks .63
21 Publication Bias 1 Sacks .77
22 Caveats Sacks
23 Economic Impact Sacks .84
24 Language 1 Added to Sacks .79
25 Search Strategy OQAQ (1) .81
26 Was the search comprehensive OQAQ (2)
27 Criteria used for deciding which studies to 
include
OQAQ (3)
28 Was bias in the selection avoided OQAQ (4) .81
29 Were the criteria used for assessing the validity 
reported?
OQAQ (5) .75
30 Was the validity of all studies referred to in the 
text assessed using appropriate criteria
OQAQ (6) .53 .60
31 Were the methods used to combine the finding 
of the relevant studies reported
OQAQ (7)
32 Were the findings of the relevant studies 
combined appropriately
OQAQ (8) .78
33 Were the conclusions made by the author 
supported by the data
OQAQ (9) .68
34 Overall Summary OQAQ (10)
35. Publication Bias 2 Additional (1) .80
36 Publication Status Additional (2) .77
37 Language 2 Additional (3) .63
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Table 2: AMSTAR is a measurement tool created to assess the methodological quality of systematic reviews.
1. Was an 'a priori' design provided?
The research question and inclusion criteria should be established before the conduct of the review.
 Yes
 No
 Can't answer
 Not applicable
2. Was there duplicate study selection and data extraction?
There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
 Yes
 No
 Can't answer
 Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases used (e.g. Central, EMBASE, 
and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All 
searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the 
particular field of study, and by reviewing the references in the studies found.
 Yes
 No
 Can't answer
 Not applicable
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The authors should state whether 
or not they excluded any reports (from the systematic review), based on their publication status, language etc.
 Yes
 No
 Can't answer
 Not applicable
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided.
 Yes
 No
 Can't answer
 Not applicable
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and 
outcomes. The ranges of characteristics in all the studies analyzed e.g. age, race, sex, relevant socioeconomic data, disease 
status, duration, severity, or other diseases should be reported.
 Yes
 No
 Can't answer
 Not applicable
7. Was the scientific quality of the included studies assessed and documented?
'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only 
randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies 
alternative items will be relevant.
 Yes
 No
 Can't answer
 Not applicable
8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the 
review, and explicitly stated in formulating recommendations.
 Yes
 No
 Can't answer
 Not applicable
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi-
squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical 
appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?).
 Yes
 No
 Can't answer
 Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or 
statistical tests (e.g., Egger regression test).
 Yes
 No
 Can't answer
 Not applicable
11. Was the conflict of interest stated?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
 Yes
 No
 Can't answer
 Not applicable
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quality assessment criteria for systematic reviews. Feed-
back from CADTH reviewers has been very positive. Fur-
ther preliminary experience suggests that AMSTAR has
good reliability and convergent validity also suggesting
that appraisers can apply it in a consistent way.
AMSTAR, if used widely after external validation, could
also enable methodological research (i.e. meta-regression
of item of AMSTAR and effect size of reviews). Our instru-
ment is an attempt to achieve consensus amongst current
mainstream opinions. Inevitably, new evidence will mod-
ify current thinking in some areas and at that point the
AMSTAR will be updated. This is indeed likely to be the
case with techniques to identify and quantify publication
bias [33]. Although a number of alternative tests for pub-
lication bias exist, none has yet been validated [34].
Publication bias remains an area of contention amongst
those who assess the quality of systematic reviews. It
remains a research priority because it is unclear what the
impact of publication bias is on making decisions in
health care. We are aware of the 20 years of work that has
gone in this area of research. This has given us some clear
answers as to the effect publication bias may have on the
overall results of estimating the impact of interventions.
AMSTAR will remain a living document and advances in
empirical methodological research will be reflected in fur-
ther improvements to the instrument.
Conclusion
A measurement tool for assessment of multiple systematic
reviews (AMSTAR) was developed. The tool consists of 11
items and has good face and content validity for measur-
ing the methodological quality of systematic reviews.
Additional studies are needed with a focus on the repro-
ducibility and construct validity of AMSTAR, before strong
recommendations can be made on its use.
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